T2EVOLVE: breakthrough alliance boosting Europe to the forefront of cancer immunotherapy

Goals of the T2EVOLVE consortium Goals of the T2EVOLVE consortium T2EVOLVE members T2EVOLVE includes innovators and pioneers in the field of immunotherapy from 9 nations and is coordinated by the Universitätsklinikum Würzburg,Germany, and Servier,France.Visit this pageto view the full list of partners. As a member, theEuropean Hematology Association (EHA)supports the development of advanced, safe, effective, and accessible engineered T-cell therapies. EHA will be...

Goals of the T2EVOLVE consortium

T2EVOLVE members

T2EVOLVE includes innovators and pioneers in the field of immunotherapy from 9 nations and is coordinated by the Universitätsklinikum Würzburg, Germany, and Servier, France. Visit this page to view the full list of partners.

As a member, the European Hematology Association (EHA) supports the development of advanced, safe, effective, and accessible engineered T-cell therapies. EHA will be responsible for the dissemination of information to assist the implementation of materials dedicated to educating patients and their families as well as a wide range of resources for Health Care Professionals. Finally, EHA will be part of a technical committee working towards analytical standards and endorsements of scientific methods.

Further information on the project will be available on the website www.t2evolve.eu and on the project's LinkedIn profile 'T2EVOLVE consortium'.

The T2EVOLVE project will have its first public appearance at the EHA-EBMT 3^rd European CAR-T Cell Meeting (Virtual, February 4-6, 2021) with a workshop on February 5  at 7:00PM CET entitled 'How to rapidly move new CAR-Ts forward from bench to bedside? Key questions and answers!'

This project receives funding from the Innovative Medicines Initiative 2 Joint Undertaking under grant agreement No 945393. This Joint Undertaking receives support from the European Union's Horizon 2020 research and innovation program and EFPIA.

Photo - https://mma.prnewswire.com/media/1430515/T2EVOLVE_tumor_cell.jpg  
Logo - https://mma.prnewswire.com/media/1430516/T2EVOLVE_Logo.jpg